Use of the popular smoking cessation drug varenicline (Champix) at a maintenance dose for longer than six weeks is associated with adverse gastrointestinal effects, new research shows.
A meta-analysis of 12 randomised trials involving 5114 smokers, found Champix used at a maintenance dose of 1mg twice a day for longer than six weeks was significantly associated with nausea, and to a lesser extent, constipation and flatulence, compared with placebo.
Canadian reviewers said all of the studies reported an association between Champix use and nausea, translating into almost a five-fold risk of nausea with use of Champix.
Eight studies showed a relationship between Champix use and a 2.4-fold risk of constipation, and five studies reported adverse events of flatulence with...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.